Latest News

Explore the risks of bypassing dermatologists for DIY skincare and telehealth treatments, highlighting real patient experiences and expert insights.

Zasocitinib emerges as a promising oral therapy for psoriasis, achieving significant skin clearance and favorable safety in recent phase 3 trials.

At a recent Case-Based Roundtable event, Aaron Farberg, MD, moderated a discussion of challenging atopic dermatitis cases spanning adult, adolescent, and pediatric patients.

In part 2 of this supplement, experts discuss therapies for inflammatory acne

Porter leads a dynamic roundtable on hidradenitis suppurativa, exploring innovative treatments and collaborative strategies for improved patient outcomes.

Early-phase development introduces a potential first-in-class oral approach targeting type 2 inflammation relevant to dermatologic diseases.

Soligenix reveals promising results from its phase 2a study of SGX302, a novel therapy for mild-to-moderate psoriasis, enhancing patient experience and efficacy.

New research reveals that combining DecisionDx-UM and PRAME significantly enhances survival predictions for uveal melanoma.

Discover the latest breakthroughs in atopic dermatitis and psoriasis treatments for 2025, enhancing patient care and individualizing therapy options.

An expert panel endorses Castle Biosciences’ 31-GEP test, enhancing melanoma management through personalized risk assessment and improved prognostic accuracy.

At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, discussed psoriasis in high-impact sites, overall psoriatic disease, and available therapies.

Wildfire air pollution significantly increases atopic dermatitis and itch-related dermatologic visits, highlighting the urgent need for skin protection during poor air quality.

In part 2 of this Case-Based Roundtable supplement, experts discuss therapeutic options for psoriasis when considering involvement of special areas.